Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort
Authors' conclusion
Approximately 30% of patients who had reported COVID-19-like symptoms had SARS-CoV-2 antibodies. The seroprevalence of SARS-CoV-2 antibodies after reported COVID-19-like symptoms was similar in IMIDT patients with and without imed compared to controls.
Study context
- Population
- Participants of the IENIMINI cohort (Netherlands) who reported COVID-19-like symptoms between March 2020 and November 2020
- Participants
- 562 usable samples
- Exposure
- IMIDT patients with and without immunosuppressive medication vs controls
- IMIDT with imedn = 202
- IMIDT without imedn = 16 3
- Controlsn = 197reference
- Outcome
- Presence of SARS-CoV-2 antibodies
Methodological detailssubstudy of the IENIMINI cohort, fingerprick capillary blood sample, total antibody assay
- Substudy of the IENIMINI cohort
- Fingerprick capillary blood sample
- Total antibody assay
Main finding
As reported in the abstract
SARS-CoV-2 antibody positive
Observational data: associations, not effects.
Further findings
Seroprevalence by sex, bDMARD use, and serious disease period (dyspnoea and fever)
- Not statistically different between the three groups
Original publication
Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort. Scand J Rheumatol. Published 14 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →